Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Bicara Therapeutics Inc. ...

    NASDAQ: BCAX · Real-Time Price · USD
    8.70
    -0.11 (-1.25%)
    At close: Jun 27, 2025, 3:59 PM
    8.71
    0.11%
    After-hours: Jun 27, 2025, 04:34 PM EDT

    Bicara Therapeutics Common Stock Statistics

    Share Statistics

    Bicara Therapeutics Common Stock has 54.54M shares outstanding. The number of shares has increased by null% in one year.

    Shares Outstanding

    n/a
    		 54.54M

    Shares Change (YoY)

    n/a
    		 n/a

    Shares Change (QoQ)

    n/a
    		 n/a

    Owned by Institutions (%)

    n/a
    		 85.26%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 3,496

    FTD / Avg. Volume

    n/a
    		 0.42%

    Short Selling Information

    The latest short interest is 6.58M, so 12.06% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.58M

    Short % of Shares Out

    n/a
    		 12.06%

    Short % of Float

    n/a
    		 18.88%

    Short Ratio (days to cover)

    n/a
    		 4.37

    Valuation Ratios

    The PE ratio is -43.05 and the forward PE ratio is -3.36. Bicara Therapeutics Common Stock's PEG ratio is 0.72.

    PE Ratio

    n/a
    		 -43.05

    Forward PE

    n/a
    		 -3.36

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 3.8

    PB Ratio

    n/a
    		 5.95

    P/FCF Ratio

    n/a
    		 -39.13

    PEG Ratio

    n/a
    		 0.72
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Common Stock.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 27.93

    Quick Ratio

    n/a
    		 27.93

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,236,272.73

    Employee Count

    n/a
    		 55

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 187K

    Effective Tax Rate

    n/a
    		 -0.28%

    Stock Price Statistics

    The stock price has increased by null% in the last 52 weeks. The beta is -2.39, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.

    Beta

    n/a
    		 -2.39

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 12.22

    200-Day Moving Average

    n/a
    		 n/a

    Relative Strength Index (RSI)

    n/a
    		 35.94

    Average Volume (20 Days)

    n/a
    		 835,570

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -82.39M

    Net Income

    n/a
    		 -68M

    EBITDA

    n/a
    		 -67.75M

    EBIT

    n/a
    		 -67.81M

    Earnings Per Share (EPS)

    n/a
    		 -0.4
    Full Income Statement

    Balance Sheet

    The company has 489.71M in cash and 738K in debt, giving a net cash position of 488.97M.

    Cash & Cash Equivalents

    n/a
    		 489.71M

    Total Debt

    n/a
    		 738K

    Net Cash

    n/a
    		 488.97M

    Retained Earnings

    n/a
    		 -221.02M

    Total Assets

    n/a
    		 478.08M

    Working Capital

    n/a
    		 451.63M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -74.75M and capital expenditures -71K, giving a free cash flow of -74.82M.

    Operating Cash Flow

    n/a
    		 -74.75M

    Capital Expenditures

    n/a
    		 -71K

    Free Cash Flow

    n/a
    		 -74.82M

    FCF Per Share

    n/a
    		 -0.45
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    BCAX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BCAX is $33, which is 274.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $33

    Price Target Difference

    n/a
    		 274.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 15.83

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist